A Mouse Model for Microbeam Radiation Therapy of the Lung

Elisabeth Schuetke (1) , Sam Bayat (2, 3) , Stefan Bartzsch (4) , Elke Brauer-Krisch (5) , Valentin Djonov (6) , Stefan Fiedler (7) , Cristian Fernandez-Palomo (6) , Felix Jaekel (1) , Paolo Pellicioli (5) , Verdiana Trappetti (6) , Guido Hildebrandt (1)

1 University Medical Center Rostock
2 STROBE - Synchrotron Radiation for Biomedicine = Rayonnement SynchroTROn pour la Recherche BiomédicalE
3 UGA - Université Grenoble Alpes
4 TUM - Technische Universität Munchen - Technical University Munich - Université Technique de Munich
5 ESRF - European Synchrotron Radiation Facility [Grenoble]
6 UNIBE - Universität Bern / University of Bern
7 EMBL - European Molecular Biology Laboratory

Purpose: Radiation therapy is an important treatment component for patients with lung cancer. However, the survival time gained with clinical radiation therapy techniques is relatively short. Data from preclinical experiments suggest that synchrotron microbeam radiation therapy could be much better suited to control malignant brain tumors than current clinical concepts of radiation therapy. Even at peak doses of several hundred gray, the extent of functional deficits is low. Methods and Materials: We have developed the first mouse model to study the effects of microbeam irradiation in lung tissue. Results: Up to peak doses of 400 Gy, no acute adverse effects were seen. Conclusion: This model is well suited to explore the potential of microbeam radiation therapy in the treatment of lung cancer and the response of normal lung tissue and organs at risk. (C) 2021 The Authors. Published by Elsevier Inc.

Mots clés: RADIOTHERAPY; UNIFORM

Domaines: Sciences du Vivant [q-bio]

Elisabeth Schuetke, Sam Bayat, Stefan Bartzsch, Elke Brauer-Krisch, Valentin Djonov, et al.. A Mouse Model for Microbeam Radiation Therapy of the Lung. International Journal of Radiation Oncology, Biology, Physics, 2021, 110 (2), pp.521-525. ⟨10.1016/j.ijrobp.2020.12.030⟩. ⟨hal-03722626⟩